These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 36207308)

  • 1. Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer.
    Kennedy EM; Denslow A; Hewett J; Kong L; De Almeida A; Bryant JD; Lee JS; Jacques J; Feau S; Hayes M; McMichael EL; Wambua D; Farkaly T; Rahmeh AA; Herschelman L; Douglas D; Spinale J; Adhikari S; Deterling J; Scott M; Haines BB; Finer MH; Ashburn TT; Quéva C; Lerner L
    Nat Commun; 2022 Oct; 13(1):5907. PubMed ID: 36207308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and application of oncolytic viruses for cancer immunotherapy.
    Ylösmäki E; Cerullo V
    Curr Opin Biotechnol; 2020 Oct; 65():25-36. PubMed ID: 31874424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
    Marchini A; Scott EM; Rommelaere J
    Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
    Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia.
    Wang W; Liu S; Dai P; Yang N; Wang Y; Giese RA; Merghoub T; Wolchok J; Deng L
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic delivery of glycosylated-PEG-masked oncolytic virus enhances targeting of antitumor immuno-virotherapy and modulates T and NK cell infiltration.
    Liang Y; Wang B; Chen Q; Fu X; Jiang C; Lin Z; Zhuang Q; Zeng Y; Liu X; Zhang D
    Theranostics; 2023; 13(15):5452-5468. PubMed ID: 37908722
    [No Abstract]   [Full Text] [Related]  

  • 7. Characterization of a full-length infectious cDNA clone and a GFP reporter derivative of the oncolytic picornavirus SVV-001.
    Poirier JT; Reddy PS; Idamakanti N; Li SS; Stump KL; Burroughs KD; Hallenbeck PL; Rudin CM
    J Gen Virol; 2012 Dec; 93(Pt 12):2606-2613. PubMed ID: 22971818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal timing of PD-1 blockade in combination with oncolytic virus therapy.
    Nguyen HM; Bommareddy PK; Silk AW; Saha D
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):971-980. PubMed ID: 34033895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers.
    Reddy PS; Burroughs KD; Hales LM; Ganesh S; Jones BH; Idamakanti N; Hay C; Li SS; Skele KL; Vasko AJ; Yang J; Watkins DN; Rudin CM; Hallenbeck PL
    J Natl Cancer Inst; 2007 Nov; 99(21):1623-33. PubMed ID: 17971529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them.
    Hu PY; Fan XM; Zhang YN; Wang SB; Wan WJ; Pan HY; Mou XZ
    Appl Microbiol Biotechnol; 2020 Oct; 104(19):8231-8242. PubMed ID: 32816087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virus-Protein Corona Replacement Strategy to Improve the Antitumor Efficacy of Intravenously Injected Oncolytic Adenovirus.
    Huang H; Liu M; Sun M; Duan S; Pan S; Liu P; Cheng Z; Ergonul O; Can F; Wang Z; Pang Z; Liu F
    ACS Nano; 2023 Aug; 17(15):14461-14474. PubMed ID: 37367941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic viruses and antibodies: are they more successful when delivered separately or when engineered as a single agent?
    Wan PK; Fernandes RA; Seymour LW
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37541690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic Viruses and Cancer Immunotherapy.
    Malhotra J; Kim ES
    Curr Oncol Rep; 2023 Jan; 25(1):19-28. PubMed ID: 36441447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Boarding Oncolytic Viruses onto Tumor-Homing Bacterium-Vessels for Augmented Cancer Immunotherapy.
    Sun M; Yang S; Huang H; Gao P; Pan S; Cheng Z; He Z; Wang Z; Sun J; Liu F
    Nano Lett; 2022 Jun; 22(12):5055-5064. PubMed ID: 35583490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic viruses and their application to cancer immunotherapy.
    Chiocca EA; Rabkin SD
    Cancer Immunol Res; 2014 Apr; 2(4):295-300. PubMed ID: 24764576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.
    Chowaniec H; Ślubowska A; Mroczek M; Borowczyk M; Braszka M; Dworacki G; Dobosz P; Wichtowski M
    Front Immunol; 2024; 15():1375433. PubMed ID: 38576614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging field of oncolytic virus-based cancer immunotherapy.
    Ma R; Li Z; Chiocca EA; Caligiuri MA; Yu J
    Trends Cancer; 2023 Feb; 9(2):122-139. PubMed ID: 36402738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features.
    Rudin CM; Poirier JT; Senzer NN; Stephenson J; Loesch D; Burroughs KD; Reddy PS; Hann CL; Hallenbeck PL
    Clin Cancer Res; 2011 Feb; 17(4):888-95. PubMed ID: 21304001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma.
    Liu Z; Zhao X; Mao H; Baxter PA; Huang Y; Yu L; Wadhwa L; Su JM; Adesina A; Perlaky L; Hurwitz M; Idamakanti N; Police SR; Hallenbeck PL; Hurwitz RL; Lau CC; Chintagumpala M; Blaney SM; Li XN
    Neuro Oncol; 2013 Sep; 15(9):1173-85. PubMed ID: 23658322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic Immunotherapy: Can't Start a Fire Without a Spark.
    Muscolini M; Tassone E; Hiscott J
    Cytokine Growth Factor Rev; 2020 Dec; 56():94-101. PubMed ID: 32826166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.